D-0085-2024 Class III Terminated

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0085-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 20, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Aug 16, 2024). Affected quantity: 480 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Nov 8, 2023
Initiation Date
Oct 20, 2023
Termination Date
Aug 16, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
480 100-count bottles

Product description

Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

Nationwide in the USA

Code information

Lot# 17212352, Exp 11/31/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0085-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0085-2024. Report a data issue: hello@regdatalab.com.